Two tiny genetic variations may provide the best clues yet for finding more precise ways to estimate prostate cancer risk and improve screening and early detection for men of African descent, report researchers from the University of Chicago and the Translational Genomics Research Institute in Phoenix.
Two tiny genetic variations may provide the best clues yet for finding more precise ways to estimate prostate cancer risk and improve screening and early detection for men of African descent, report researchers from the University of Chicago and the Translational Genomics Research Institute in Phoenix.
The researchers set out to determine whether results from four previous studies that linked genetic variations on one region of chromosome 8 to increased prostate cancer risk among Caucasians were also valid for men of African heritage. In the process, however, they found an additional genetic variation among African-American men that was an even stronger marker for cancer risk for these men.
That variation is located within a gene that plays a role in DNA repair. A malfunction in DNA repair could contribute to cancer development.
“This finding emphasizes the importance of ancestry in studying genetics,” said study author Rick Kittles, PhD. “Previous studies led us to one specific region of chromosome 8. Then this approach, which took advantage of genetic differences among African-American men, who are at very high risk for this type of cancer, led us to a different locus within that region and directly to a gene of interest.”
The study was published ahead of print in the Oct. 31 online issue of Genome Research.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.